Oncobit and ID Solutions Announce Strategic Partnership
Oncobit, a leading Swiss company in precision oncology, announces a strategic partnership with ID Solutions, a French company specializing in developing innovative diagnostic solutions in oncology. The goal of this collaboration...
Aukera Therapeutics gibt Financing bekannt
Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel, recently announced that it has raised some CHF 4.5m to date and attracted new board member and investor David Urech. Other current investors...
Placement of USD 110 Million Financing of Oculis Holding AG
Oculis Holding AG (Nasdaq: OCS; XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, announced the placements of...
RetinAI acquired by EssilorLuxottica
EssilorLuxottica, a global leader in vision care and eyewear, has acquired Ikerian AG, a health technology company operating under the RetinAI brand, specializing in AI and data management in eyecare.
Nuclidium AG closes Series B financing round
NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, announced the successful closing of its Series B financing round, raising CHF 79m (EUR 84m).
Snyk acquires Invariant Labs AG
Snyk Ltd., the leader in secure AI software development, acquires Invariant Labs AG, an AI security research company and spin-off of ETH Zurich based in Zurich.
Mosanna Therapeutics raises USD 80m in Series-A-Funding
Mosanna Therapeutics AG closed its USD 80m Series A funding round.
GlycoEra AG closes Series-B-financing round
GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, announced the closing of an oversubscribed USD 130m Series-B-financing.
Aktiia Secures USD 42m Series-B-Funding to Expand into New Markets
Aktiia, a blood pressure intelligence platform, has completed an oversubscribed USD 42m Series-B funding-round, bringing the company's total funding to date to USD 100m.
HAYA Therapeutics raises USD 65m in Series-A-Funding
HAYA Therapeutics AG has successfully closed its Series-A-financing round of USD 65m – an important step toward its vision of reprogramming disease-causing cellular states.